Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Oncopeptides publishes disclosure document regarding rights issue

MARKN.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.

Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) publishes disclosure document in connection with the Company’s new share issue with preferential rights for existing shareholders of approximately SEK 200 million, as resolved by the Board of Directors on 19 February 2026 by virtue of the authorization from the Annual General Meeting held on 22 May 2025 (the “Rights Issue”). The disclosure document has been registered with the Swedish Financial Supervisory Authority and is available at the Company’s website.

Disclosure document

In connection with the Rights Issue, the Company has prepared a disclosure document in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation (in Swedish only).

Today, Oncopeptides announces that the disclosure document has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website www.oncopeptides.com and on www.dnbcarnegie.se (in Swedish only).

 
Preliminary timetable for the Rights Issue
The below timetable for the Rights Issue is preliminary and may be adjusted.

 

Record date for the right to receive subscription rights26 February 2026
Trading in subscription rights2 – 11 March 2026
Subscription period2 – 16 March 2026
Trading in paid subscribed shares (BTA)2 – 23 March 2026
Announcement of the outcome of the Rights IssueAround 18 March 2026

 

Advisors

DNB Carnegie Investment Bank AB acts as Sole Global Coordinator and Sole Bookrunner in connection with the Rights Issue. Advokatfirman Vinge KB is legal advisor to the Company.